ArticleSouthern medical journal2025
Safety and Cost-Effectiveness of Hospital at Home in Patients with COVID-19.
Article in Southern medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Associations with Hospital Escalation Among COVID-19 Patients Receiving Remdesivir in a Hospital-at-Home Service: A Real-World Cohort Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe coronavirus disease 2019 (COVID-19) pandemic significantly affected the capacity of health systems across the United States. Although not widely used before the pandemic, the hospital-at-home (HaH) model emerged as a potential strategy to alleviate hospital burden by providing hospital-level care in the home setting. This study aims to evaluate the safety, clinical effectiveness, and cost-efficiency of a HaH program for patients with COVID-19, comparing these outcomes with those of traditional in-hospital care.
methodsA retrospective matched case-control study was conducted at a major academic medical center in the southeastern United States. The study included 200 patients with confirmed COVID-19, 100 of whom were enrolled in the HaH program between February 1, 2021 and January 31, 2022, and 100 served as matched controls who received conventional hospital care. Matching criteria included age, sex, and admission to the intensive care unit. The primary outcomes assessed were 30-day readmission rates and inpatient length of stay (iLOS). Secondary outcomes included total length of stay (tLOS), emergency department visits within 30 days, and detailed cost analysis, including fixed and variable costs.
resultsThe analysis included 200 patients (mean age 50.4 years, standard deviation 14.2; 55% female). There were no significant differences between the HaH and control groups in terms of age, sex, or intensive care unit admission rates. The study found no statistically significant differences in 30-day readmissions (11% vs 14%,
conclusionsThe HaH program for COVID-19 patients offered a safe alternative to traditional hospitalization, with similar clinical outcomes and significant reductions in inpatient costs. The shorter iLOS suggests potential benefits in hospital resource management during surge periods, while the longer tLOS highlights the need for optimized patient selection and care strategies in the home setting. Further research is warranted to explore the long-term economic implications and patient outcomes of HaH programs, particularly during heightened demand, on healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.